TLC is a leading public biopharmaceutical company headquartered in Taiwan focused on the research, development and commercialization of products based on its proprietary drug delivery technologies. As a company with little name recognition outside of its home country, TLC wanted to be known to a wider consumer and investor audience and hoped to increase its exposure to include the U.S., Europe and broader Southeast Asia markets, with the aim of attracting a new cross-section of investors and generating additional research partnerships and deal-making opportunities.
We began with our Messaging and Positioning (MAP) program to develop targeted messages for English language investors in the U.S. & Europe. Once complete, we focused on introducing the TLC executives to key media contacts in target markets and securing significant coverage for the company in trade publications, such as BioCentury and BioWorld. In addition, we were able to position the company’s president, George Yeh, as a thought leader with perspective on the biotechnology industry in Asia. To accomplish this, we worked to secure opportunities for Mr. Yeh to provide commentary on the burgeoning innovation hub in Taipei with outlets including Bloomberg First Word. We were ultimately successful in driving interest for TLC within new markets and expanding the company’s and executives’ thought leadership reach within and beyond Taiwan.